PDE5 inhibitors: targeting erectile dysfunction in diabetics

Erectile dysfunction (ED) is strongly linked to cardiovascular disease (CVD), especially in diabetics. ED is associated with deleterious changes in the overall vasculature and is recognized as an indicator of higher risk for adverse cardiovascular events. Endothelial dysfunction, vascular smooth muscle changes and increased fibrosis are indicated as major players in both ED and CVD. ED in diabetics is more refractory to acute treatment with phosphodiesterase-5 (PDE5) inhibitors (Viagra, Cialis, Levitra, Zydena) than in non-diabetics, but recent studies indicate that chronic administration of these drugs improves endothelial function, preserves vascular smooth muscle and decreases fibrotic changes. Use of PDE5 inhibitors in pre-diabetic and diabetic men may protect cardiovascular health, including vascular function in penile tissues.

► Use of PDE5 inhibitors may improve endothelial function thereby improving overall vascular health.
► PDE5 inhibitors improve VSM function and decrease fibrosis in models of diabetes.
► Chronic use of PDE5 inhibitors alone or with other medications may ameliorate diabetes-induced ED.